SCHEMBL1269539

SCHEMBL1269539

CCC(=O)c1nc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Sc1ccc(S(=O)(=O)N2CCOCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.43
▸ MEN1 O00255 5/20 0.43
▸ MAPT P10636 6/20 0.42
▸ GAA P10253 2/20 0.42
▸ LMNA P02545 5/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ HTT P42858 3/20 0.41
▸ MAPK1 P28482 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ BRCA1 P38398 1/20 0.40
▸ PTGDR2 Q9Y5Y4 2/20 0.39
▸ PTGDR Q13258 1/20 0.39
▸ APOBEC3G Q9HC16 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ NOD2 Q9HC29 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ ALOX5 P09917 1/20 0.38
▸ TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269706 0.94 ALDH1A1 (0.42) KMT2AMEN1MAPTGAALMNA
SCHEMBL1268898 0.93 PTGDR2 (0.40) KMT2AMEN1MAPTGAALMNA
SCHEMBL1269360 0.92 KMT2A (0.44) KMT2AMEN1MAPTGAALMNA
SCHEMBL1269276 0.92 MAPT (0.41) KMT2AMEN1MAPTGAALMNA
SCHEMBL1269717 0.91 MEN1 (0.44) KMT2AMEN1MAPTGAALMNA
SCHEMBL1268682 0.89 KMT2A (0.43) KMT2AMEN1MAPTGAALMNA
SCHEMBL1269670 0.88 KMT2A (0.42) KMT2AMEN1MAPTGAALMNA
SCHEMBL1268503 0.87 PTGDR2 (0.41) KMT2AMEN1MAPTGAALMNA
SCHEMBL1269715 0.86 MEN1 (0.43) KMT2AMEN1MAPTGAALMNA
SCHEMBL1269799 0.86 PTGDR2 (0.40) KMT2AMEN1MAPTGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 — — EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG KMT2A 1448/4885MEN1 4841/4885MAPT 4602/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG KMT2A 1448/4885MEN1 4841/4885MAPT 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback